... pathway of its key clinical asset PBT2, now in two concurrent Phase II clinical trials in Huntington Disease and Alzheimer's Disease. Recruitment was completed for both clinical trials on time and within budget. Results are expected to be reported ...
http://www.biospace.com/news_story.aspx?StoryID=291660&full=1
http://www.biospace.com/news_story.aspx?StoryID=291660&full=1
No comments:
Post a Comment